Nelitolimod

N/A

Report date: 2026/03/20 20:03:07
NME

Base Information

Drug NameNelitolimod
Drug Alias NameISS-ODN SD-101SD-101-DynavaxSD-101 (trisalus life sciences)
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide
Mechanisms of ActionImmunostimulantsToll like receptor 9 agonists
TargetsToll like receptor 9
Therapy Area/IndicationsUveal melanomaSolid tumoursProstatic Neoplasms +[19] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesPolandNew Zealand +[5] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesTriSalus Life Sciences Inc
China Registration ClassN/A

Develop Information

Active CompaniesThe University Of California DavisDynavax Technologies CorpNational Cancer Institute +[6] 
Inactive CompaniesN/A
Active IndicationsProstatic NeoplasmsPancreatic NeoplasmsColorectal Neoplasms +[9] 
Inactive IndicationsUveal melanomaSolid tumoursHead and Neck Neoplasms +[10] 

Other Information

ATC CodeN/A
Related LinksN/A